PBIO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PBIO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Pressure BioSciences's PE Ratio without NRI is 0.00. Pressure BioSciences's 5-Year EBITDA growth rate is 35.40%. Therefore, Pressure BioSciences's PEG Ratio for today is 0.00.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Pressure BioSciences's PEG Ratio or its related term are showing as below:
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
The historical data trend for Pressure BioSciences's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pressure BioSciences Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
PEG Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
Pressure BioSciences Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
PEG Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
For the Medical Devices subindustry, Pressure BioSciences's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Pressure BioSciences's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Pressure BioSciences's PEG Ratio falls into.
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.
Pressure BioSciences's PEG Ratio for today is calculated as
PEG Ratio | = | PE Ratio without NRI | / | 5-Year EBITDA Growth Rate* |
= | / | 35.40 | ||
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Pressure BioSciences (OTCPK:PBIO) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Thank you for viewing the detailed overview of Pressure BioSciences's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Daniel Joseph Shea | officer: Senior Vice President & CFO | 2 MINUTEMAN ROAD, MEDFIELD MA 02052 |
Bradford Addison Young | officer: Chief Commercial Officer | 513 LITTLE JOHN HILL, ANNAPOLIS MD 21405 |
Richard T Schumacher | director, officer: Chief Executive Officer | 375 WEST STREET, WEST BRIDGEWATER MA 02379 |
Nathan Lawrence | other: VP Sales and Marketing | 321 MANLEY STREET, WEST BRIDGEWATER MA 02379 |
Richard Thomley | officer: Chief Financial Officer | C/O PRESSURE BIOSCIENCES, INC., 14 NORFOLK AVE., SOUTH EASTON MA 02375 |
Kevin Pollack | director | 150 RAINVILLE ROAD, TARPON SPRINGS FL 34689 |
Michael S Urdea | director | 100 BUNCE MEADOWS DRIVE, ALAMO CA 94507 |
Alexander V Lazarev | officer: VP of REsearch and Development | 18 WINCHESTER DRIVE, LEXINGTON MA 02420 |
Edmund Y Ting | officer: Senior VP of Engineering | 23642 123RD PLACE SOUTHEAST, KENT WA 48031 |
Vito J Mangiardi | director | 12 POINT GALLINAS ROAD, SAN RAFAEL CA 94903 |
Jeffrey N Peterson | director | 1031 SHORELINE DRIVE, SAN MATEO CA 94404 |
Mir Conrad F | officer: CFO | 19 BRIER LANE, CLIFTON NJ 07012 |
Clayton A Struve | 10 percent owner | 175 W JACKSON BLVD, SUITE 440, CHICAGO IL 60604 |
Css Llc/il | other: (a) | 175 WEST JACKSON BLVD, SUITE 440, CHICAGO IL 60604 |
R Wayne Fritzsche | director | 835 GREENS PARKWAY, SUITE 150, HOUSTON TX 77067 |
From GuruFocus
By ACCESSWIRE • 12-12-2023
By ACCESSWIRE • 08-17-2023
By ACCESSWIRE • 09-08-2023
By ACCESSWIRE ACCESSWIRE • 06-13-2023
By ACCESSWIRE • 12-21-2023
By ACCESSWIRE • 08-22-2023
By ACCESSWIRE • 09-22-2023
By ACCESSWIRE • 08-09-2023
By sperokesalga sperokesalga • 06-01-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.